MBX Biosciences is a clinical-stage biopharmaceutical company that develops novel precision peptide therapies for endocrine and metabolic disorders. Its products include MBX 2109, a treatment of hyperparathyroidism, MBX 1416, a therapy for post-bariatric hypoglycemia, and MBX 4291, a long-acting GLP-1/GIP receptor co-agonist for obesity.